ARQIS has advised the French veterinary pharmaceuticals group Ceva Santé Animale SA on the acquisition of the veterinary biopharmaceutical and R&D activities of IDT Biologika GmbH, a pharmaceutical company based in Dessau-Roßlau.
The transaction enables Ceva to expand its veterinary and animal public health portfolio, while IDT will focus on the production of human medical biotechnological vaccines and active ingredients for the national and international market. Ceva is also planning substantial investments in the new Global Innovation Centre for Swine Vaccines at the existing IDT sites in Dessau and Riems. The center will strengthen Ceva’s biological research and development capabilities by bringing together two highly qualified R&D teams and their innovative product pipelines with high growth potential.
Award-winning innovation and quality — IDT focuses on contract manufacturing for human and animal health. IDT Biologika has received international accolades for the development and manufacturing of new vaccines.
Ceva is a multinational veterinary pharmaceutical group based in Libourne, France, founded in 1999. The company specialises in the research, development, production and marketing of pharmaceutical products and vaccines for farm animals (ruminants, pigs and poultry) and pets. Ceva is present in 110 countries and employs 5,700 people worldwide.
The ARQIS team was led by Dr. Jörn-Christian Schulze, who advised Ceva with the support of the in-house team led by Valérie Mazeaud (Board Member Legal).
Involved fees earner: Jörn-Christian Schulze – Arqis;
Law Firms: Arqis;
Clients: Ceva Santé Animale SA;